| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Aberrant transcription factors in the cancers of the pancreas
|
Uddin, Md. Hafiz
|
|
|
104-105 |
P2 |
p. 28-45
|
article
|
| 2 |
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine
|
Gowd, Vemana
|
|
|
104-105 |
P2 |
p. 624-644
|
article
|
| 3 |
Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory
|
Kashima, Jumpei
|
|
|
104-105 |
P2 |
p. 386-395
|
article
|
| 4 |
Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy
|
Su, Xin
|
|
|
104-105 |
P2 |
p. 929-942
|
article
|
| 5 |
Advances in the DNA Nanotechnology for the Cancer Biomarkers Analysis: Attributes and Applications
|
Xia, Ling-Ying
|
|
|
104-105 |
P2 |
p. 1105-1119
|
article
|
| 6 |
APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis
|
Schrock, Morgan S.
|
|
|
104-105 |
P2 |
p. 80-91
|
article
|
| 7 |
Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer
|
Yin, Xiaomeng
|
|
|
104-105 |
P2 |
p. 146-159
|
article
|
| 8 |
Artificial intelligence in radiotherapy
|
Li, Guangqi
|
|
|
104-105 |
P2 |
p. 160-171
|
article
|
| 9 |
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis
|
Hosseininasab-nodoushan, Seyed-Abolfazl
|
|
|
104-105 |
P2 |
p. 923-928
|
article
|
| 10 |
A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design
|
Morfouace, M.
|
|
2018
|
104-105 |
P2 |
p. 158-165
|
article
|
| 11 |
Bacteria as a treasure house of secondary metabolites with anticancer potential
|
Mohan, Chakrabhavi Dhananjaya
|
|
|
104-105 |
P2 |
p. 998-1013
|
article
|
| 12 |
Bacteria-based immune therapies for cancer treatment
|
Howell, Lars M.
|
|
|
104-105 |
P2 |
p. 1163-1178
|
article
|
| 13 |
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders
|
Neganova, Margarita E.
|
|
|
104-105 |
P2 |
p. 805-833
|
article
|
| 14 |
Biomarkers for checkpoint inhibition in hematologic malignancies
|
Atanackovic, Djordje
|
|
2018
|
104-105 |
P2 |
p. 198-206
|
article
|
| 15 |
Biomimetic approaches for targeting tumor-promoting inflammation
|
Parodi, Alessandro
|
|
|
104-105 |
P2 |
p. 555-567
|
article
|
| 16 |
Breast cancer genomics and immuno-oncological markers to guide immune therapies
|
Hammerl, D.
|
|
2018
|
104-105 |
P2 |
p. 178-188
|
article
|
| 17 |
Cancer depends on fatty acids for ATP production: A possible link between cancer and obesity
|
Lee, Ho
|
|
|
104-105 |
P2 |
p. 347-357
|
article
|
| 18 |
Cancer evolution: Special focus on the immune aspect of cancer
|
Hu, Xiao
|
|
|
104-105 |
P2 |
p. 420-435
|
article
|
| 19 |
Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials
|
Yadav, Dhananjay
|
|
|
104-105 |
P2 |
p. 909-922
|
article
|
| 20 |
Cancer stem cells: Regulation programs, immunological properties and immunotherapy
|
Zhang, Dingxiao
|
|
2018
|
104-105 |
P2 |
p. 94-106
|
article
|
| 21 |
Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer
|
Ganguly, Koelina
|
|
|
104-105 |
P2 |
p. 511-520
|
article
|
| 22 |
Chemokines and chemokine receptors in colorectal cancer; multifarious roles and clinical impact
|
Braoudaki, Maria
|
|
|
104-105 |
P2 |
p. 436-449
|
article
|
| 23 |
Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics
|
Srivastava, Saumya
|
|
|
104-105 |
P2 |
p. 233-246
|
article
|
| 24 |
Chemokines driven ovarian cancer progression, metastasis and chemoresistance: Potential pharmacological targets for cancer therapy
|
Bose, Subhankar
|
|
|
104-105 |
P2 |
p. 568-579
|
article
|
| 25 |
Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications
|
Mehraj, Umar
|
|
|
104-105 |
P2 |
p. 769-783
|
article
|
| 26 |
Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer
|
Chakraborty, Abhishek A.
|
|
|
104-105 |
P2 |
p. 34-42
|
article
|
| 27 |
Corrigendum to “Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers” [Semin. Cancer Biol. 83 (2022) 556–569]
|
Chen, Kuo
|
|
|
104-105 |
P2 |
p. 1222
|
article
|
| 28 |
Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1
|
Lawler, Jack
|
|
|
104-105 |
P2 |
p. 126-135
|
article
|
| 29 |
Cullin-RING Ligase 5: Functional characterization and its role in human cancers
|
Zhao, Yongchao
|
|
|
104-105 |
P2 |
p. 61-79
|
article
|
| 30 |
Current nano-therapeutic approaches ameliorating inflammation in cancer progression
|
Rehman, Muneeb U.
|
|
|
104-105 |
P2 |
p. 886-908
|
article
|
| 31 |
Cyclin D degradation by E3 ligases in cancer progression and treatment
|
Qie, Shuo
|
|
|
104-105 |
P2 |
p. 159-170
|
article
|
| 32 |
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment
|
Bhatia, Rakesh
|
|
|
104-105 |
P2 |
p. 499-510
|
article
|
| 33 |
Dendrimers as nanoscale vectors: Unlocking the bars of cancer therapy
|
Dey, Asmita Deka
|
|
|
104-105 |
P2 |
p. 396-419
|
article
|
| 34 |
Dissenting degradation: Deubiquitinases in cell cycle and cancer
|
Bonacci, Thomas
|
|
|
104-105 |
P2 |
p. 145-158
|
article
|
| 35 |
Dynamic impact of virome on colitis and colorectal cancer: Immunity, inflammation, prevention and treatment
|
Wang, Zhihan
|
|
|
104-105 |
P2 |
p. 943-954
|
article
|
| 36 |
Editorial Board
|
|
|
|
104-105 |
P2 |
p. ii
|
article
|
| 37 |
Editorial Board
|
|
|
|
104-105 |
P2 |
p. ii
|
article
|
| 38 |
Editorial Board & Publication Information
|
|
|
2018
|
104-105 |
P2 |
p. IFC
|
article
|
| 39 |
Emerging applications of bacteria as antitumor agents
|
Kalia, Vipin Chandra
|
|
|
104-105 |
P2 |
p. 1014-1025
|
article
|
| 40 |
Emerging biomarkers for cancer immunotherapy in melanoma
|
Axelrod, Margaret L.
|
|
2018
|
104-105 |
P2 |
p. 207-215
|
article
|
| 41 |
Emerging biomarkers for immune checkpoint inhibition in lung cancer
|
Cyriac, George
|
|
2018
|
104-105 |
P2 |
p. 269-277
|
article
|
| 42 |
Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers
|
Lee, Belinda
|
|
2018
|
104-105 |
P2 |
p. 241-252
|
article
|
| 43 |
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
|
Lhuillier, Claire
|
|
2018
|
104-105 |
P2 |
p. 125-134
|
article
|
| 44 |
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment
|
Monavarian, Mehri
|
|
|
104-105 |
P2 |
p. 709-719
|
article
|
| 45 |
Emerging role of nanoparticles in the diagnostic imaging of gastrointestinal cancer
|
Zhou, Jianfeng
|
|
|
104-105 |
P2 |
p. 580-594
|
article
|
| 46 |
Emerging targets in cancer immunotherapy
|
Burugu, Samantha
|
|
2018
|
104-105 |
P2 |
p. 39-52
|
article
|
| 47 |
Emerging trends in the application of gold nanoformulations in colon cancer diagnosis and treatment
|
Aldahhan, Razan
|
|
|
104-105 |
P2 |
p. 1056-1065
|
article
|
| 48 |
Epigenetic regulation of CXCR4 signaling in cancer pathogenesis and progression
|
Alsayed, Reem Khaled M.E.
|
|
|
104-105 |
P2 |
p. 697-708
|
article
|
| 49 |
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives
|
Ansari, Mohammad Azam
|
|
|
104-105 |
P2 |
p. 678-696
|
article
|
| 50 |
Extracellular vesicles in cancer therapy
|
Wang, Shizhen Emily
|
|
|
104-105 |
P2 |
p. 296-309
|
article
|
| 51 |
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy
|
Kumar, Ajay
|
|
|
104-105 |
P2 |
p. 54-68
|
article
|
| 52 |
Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment
|
Gevaert, Thomas
|
|
2018
|
104-105 |
P2 |
p. 216-227
|
article
|
| 53 |
Genomics and emerging biomarkers for immunotherapy of colorectal cancer
|
Kather, Jakob Nikolas
|
|
2018
|
104-105 |
P2 |
p. 189-197
|
article
|
| 54 |
Green nanoparticles as multifunctional nanomedicines: Insights into anti-inflammatory effects, growth signaling and apoptosis mechanism in cancer
|
Naseer, Faiza
|
|
|
104-105 |
P2 |
p. 310-324
|
article
|
| 55 |
Gut microbes in gastrointestinal cancers
|
Wang, Fei
|
|
|
104-105 |
P2 |
p. 967-975
|
article
|
| 56 |
Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors
|
Curigliano, Giuseppe
|
|
2018
|
104-105 |
P2 |
p. 253-258
|
article
|
| 57 |
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
|
Solomon, Benjamin
|
|
2018
|
104-105 |
P2 |
p. 228-240
|
article
|
| 58 |
Helicobacters and cancer, not only gastric cancer?
|
Varon, Christine
|
|
|
104-105 |
P2 |
p. 1138-1154
|
article
|
| 59 |
Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy
|
van Dam, Pieter-Jan
|
|
2018
|
104-105 |
P2 |
p. 86-93
|
article
|
| 60 |
Historical perspective of tumor glycolysis: A century with Otto Warburg
|
Bononi, Giulia
|
|
|
104-105 |
P2 |
p. 325-333
|
article
|
| 61 |
How far have we explored fungi to fight cancer?
|
How, Chee Wun
|
|
|
104-105 |
P2 |
p. 976-989
|
article
|
| 62 |
Immune cellular components and signaling pathways in the tumor microenvironment
|
Yenyuwadee, Sasitorn
|
|
|
104-105 |
P2 |
p. 187-201
|
article
|
| 63 |
Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert
|
Li, Xiaoqi
|
|
|
104-105 |
P2 |
p. 14-27
|
article
|
| 64 |
Immune checkpoint molecules in neuroblastoma: A clinical perspective
|
Pathania, Anup S.
|
|
|
104-105 |
P2 |
p. 247-258
|
article
|
| 65 |
Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy
|
Im, Eunji
|
|
|
104-105 |
P2 |
p. 1066-1075
|
article
|
| 66 |
Immuno-oncology from the perspective of somatic evolution
|
González, Santiago
|
|
2018
|
104-105 |
P2 |
p. 75-85
|
article
|
| 67 |
Immuno-oncology-101: overview of major concepts and translational perspectives
|
Allard, B.
|
|
2018
|
104-105 |
P2 |
p. 1-11
|
article
|
| 68 |
Impact of the ileal microbiota on colon cancer
|
Roberti, Maria Paula
|
|
|
104-105 |
P2 |
p. 955-966
|
article
|
| 69 |
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments
|
Mamun, Abdullah Al
|
|
|
104-105 |
P2 |
p. 101-116
|
article
|
| 70 |
Inflammation targeted nanomedicines: Patents and applications in cancer therapy
|
Praveen, Thaggikuppe Krishnamurthy
|
|
|
104-105 |
P2 |
p. 645-663
|
article
|
| 71 |
Integration of chemokine signaling with non-coding RNAs in tumor microenvironment and heterogeneity in different cancers
|
Arora, Shweta
|
|
|
104-105 |
P2 |
p. 720-736
|
article
|
| 72 |
In the beginning, there was chaos: A perspective on the development of immuno-oncological biomarkers
|
Salgado, Roberto
|
|
2018
|
104-105 |
P2 |
p. v-vi
|
article
|
| 73 |
ITCH as a potential therapeutic target in human cancers
|
Yin, Qing
|
|
|
104-105 |
P2 |
p. 117-130
|
article
|
| 74 |
Lactate Dehydrogenase and its clinical significance in pancreatic and thoracic cancers
|
Comandatore, Annalisa
|
|
|
104-105 |
P2 |
p. 93-100
|
article
|
| 75 |
Lichens as a repository of bioactive compounds: an open window for green therapy against diverse cancers
|
Dar, Tanvir Ul Hassan
|
|
|
104-105 |
P2 |
p. 1120-1137
|
article
|
| 76 |
Mesenchymal stem/stromal cells in breast cancer development and management
|
Tu, Zhenbo
|
|
|
104-105 |
P2 |
p. 81-92
|
article
|
| 77 |
Metabolic regulation on the immune environment of glioma through gut microbiota
|
Lyu, Yingying
|
|
|
104-105 |
P2 |
p. 990-997
|
article
|
| 78 |
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential
|
Wahid, Mohd
|
|
|
104-105 |
P2 |
p. 1179-1189
|
article
|
| 79 |
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?
|
Guo, Haoyue
|
|
|
104-105 |
P2 |
p. 1190-1206
|
article
|
| 80 |
Molecular subtyping of small cell lung cancer
|
Liang, Jie
|
|
|
104-105 |
P2 |
p. 450-462
|
article
|
| 81 |
Multidimensional role of bacteria in cancer: Mechanisms insight, diagnostic, preventive and therapeutic potential
|
Mughal, Muhammad Jameel
|
|
|
104-105 |
P2 |
p. 1026-1044
|
article
|
| 82 |
Multifunctional plant virus nanoparticles in the next generation of cancer immunotherapies
|
Shahgolzari, Mehdi
|
|
|
104-105 |
P2 |
p. 1076-1085
|
article
|
| 83 |
Nanomedicine for glioblastoma: Progress and future prospects
|
Khan, Imran
|
|
|
104-105 |
P2 |
p. 172-186
|
article
|
| 84 |
Nanomedicine for urologic cancers: diagnosis and management
|
Li, Chunyang
|
|
|
104-105 |
P2 |
p. 463-475
|
article
|
| 85 |
Nanomedicines: Targeting inflammatory pathway in cancer and aging
|
Sukocheva, Olga A.
|
|
|
104-105 |
P2 |
p. 1218-1221
|
article
|
| 86 |
Nanomedicines targeting the inflammasome as a promising therapeutic approach for cell senescence
|
Chaturvedi, Swati
|
|
|
104-105 |
P2 |
p. 46-53
|
article
|
| 87 |
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways
|
Afshari, Amir R.
|
|
|
104-105 |
P2 |
p. 860-872
|
article
|
| 88 |
Nanoparticles: Attractive tools to treat colorectal cancer
|
Younis, Nour K.
|
|
|
104-105 |
P2 |
p. 1-13
|
article
|
| 89 |
Nano-targeting vascular remodeling in cancer: Recent developments and future directions
|
Giordo, Roberta
|
|
|
104-105 |
P2 |
p. 784-804
|
article
|
| 90 |
Natural products and their derivatives as immune check point inhibitors: Targeting cytokine/chemokine signalling in cancer
|
Gupta, Meenakshi
|
|
|
104-105 |
P2 |
p. 214-232
|
article
|
| 91 |
NEDD4 E3 ligase: Functions and mechanism in human cancer
|
Wang, Zhi-wei
|
|
|
104-105 |
P2 |
p. 92-101
|
article
|
| 92 |
Neoadjuvant immunotherapy in gastrointestinal cancers – The new standard of care?
|
Petricevic, Branka
|
|
|
104-105 |
P2 |
p. 834-850
|
article
|
| 93 |
Network science in clinical trials: A patient-centered approach
|
Manem, Venkata S.K.
|
|
2018
|
104-105 |
P2 |
p. 135-150
|
article
|
| 94 |
Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review
|
Xiong, Jiaqi
|
|
|
104-105 |
P2 |
p. 521-542
|
article
|
| 95 |
PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective
|
Nallasamy, Palanisamy
|
|
2018
|
104-105 |
P2 |
p. 53-65
|
article
|
| 96 |
Perspectives of using microRNA-loaded nanocarriers for epigenetic reprogramming of drug resistant colorectal cancers
|
Sukocheva, Olga A.
|
|
|
104-105 |
P2 |
p. 358-375
|
article
|
| 97 |
Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting
|
Vermaelen, K.
|
|
2018
|
104-105 |
P2 |
p. 166-177
|
article
|
| 98 |
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
|
Hegde, Priti S.
|
|
2018
|
104-105 |
P2 |
p. 117-124
|
article
|
| 99 |
Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment
|
Passiglia, F.
|
|
2018
|
104-105 |
P2 |
p. 259-268
|
article
|
| 100 |
PROTACs: A novel strategy for cancer therapy
|
Liu, Jing
|
|
|
104-105 |
P2 |
p. 171-179
|
article
|
| 101 |
Radiation therapy-induced remodeling of the tumor immune microenvironment
|
Charpentier, Maud
|
|
|
104-105 |
P2 |
p. 737-747
|
article
|
| 102 |
RBR E3 ubiquitin ligases in tumorigenesis
|
Wang, Peter
|
|
|
104-105 |
P2 |
p. 131-144
|
article
|
| 103 |
Recent advances of nanodrug delivery system in the treatment of hematologic malignancies
|
Ye, Qianling
|
|
|
104-105 |
P2 |
p. 607-623
|
article
|
| 104 |
Recent insight into the role of FBXW7 as a tumor suppressor
|
Yumimoto, Kanae
|
|
|
104-105 |
P2 |
p. 1-15
|
article
|
| 105 |
Re-establishing the comprehension of phytomedicine and nanomedicine in inflammation-mediated cancer signaling
|
Jha, Niraj Kumar
|
|
|
104-105 |
P2 |
p. 1086-1104
|
article
|
| 106 |
Regulation of pancreatic cancer therapy resistance by chemokines
|
Gautam, Shailendra K.
|
|
|
104-105 |
P2 |
p. 69-80
|
article
|
| 107 |
RNA-binding proteins and cancer metastasis
|
Wang, Shengjie
|
|
|
104-105 |
P2 |
p. 748-768
|
article
|
| 108 |
RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in cancer
|
Li, Wei
|
|
|
104-105 |
P2 |
p. 664-677
|
article
|
| 109 |
Role of the COP1 protein in cancer development and therapy
|
Song, Yizuo
|
|
|
104-105 |
P2 |
p. 43-52
|
article
|
| 110 |
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning
|
Klauschen, F.
|
|
2018
|
104-105 |
P2 |
p. 151-157
|
article
|
| 111 |
Small cell lung cancer: Novel treatments beyond immunotherapy
|
Meijer, Job-Joris
|
|
|
104-105 |
P2 |
p. 376-385
|
article
|
| 112 |
Small cell lung cancer: Subtypes and therapeutic implications
|
Wang, Walter Z.
|
|
|
104-105 |
P2 |
p. 543-554
|
article
|
| 113 |
Small cell lung cancer transformation: From pathogenesis to treatment
|
Yin, Xiaomeng
|
|
|
104-105 |
P2 |
p. 595-606
|
article
|
| 114 |
Special issue: Therapy-induced remodeling of the tumor microenvironment
|
Pietras, Alexander
|
|
|
104-105 |
P2 |
p. 476
|
article
|
| 115 |
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges
|
Indini, Alice
|
|
|
104-105 |
P2 |
p. 477-490
|
article
|
| 116 |
Targeting matrix metalloproteinases by E3 ubiquitin ligases as a way to regulate the tumor microenvironment for cancer therapy
|
Liu, Jinxin
|
|
|
104-105 |
P2 |
p. 259-268
|
article
|
| 117 |
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
|
Liu, Jing
|
|
|
104-105 |
P2 |
p. 269-279
|
article
|
| 118 |
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications
|
Greene, John
|
|
|
104-105 |
P2 |
p. 851-859
|
article
|
| 119 |
Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy
|
Nguyen, Khai M.
|
|
|
104-105 |
P2 |
p. 53-60
|
article
|
| 120 |
Targeting the tumor microenvironment of pancreatic ductal adenocarcinoma using nano-phytomedicines
|
Girish, Bala Prabhakar
|
|
|
104-105 |
P2 |
p. 1155-1162
|
article
|
| 121 |
TGF-β in developmental and fibrogenic EMTs
|
Lee, Jun Ho
|
|
|
104-105 |
P2 |
p. 136-145
|
article
|
| 122 |
The crossroads of adenosinergic pathway and epithelial-mesenchymal plasticity in cancer
|
Iser, Isabele Cristiana
|
|
|
104-105 |
P2 |
p. 202-213
|
article
|
| 123 |
The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells
|
Laba, Stephanie
|
|
|
104-105 |
P2 |
p. 1045-1055
|
article
|
| 124 |
The development and progress of nanomedicine for esophageal cancer diagnosis and treatment
|
Li, Xiaokun
|
|
|
104-105 |
P2 |
p. 873-885
|
article
|
| 125 |
The evolutionary legacy of immune checkpoint inhibitors
|
Kaushik, Itishree
|
|
|
104-105 |
P2 |
p. 491-498
|
article
|
| 126 |
The functions and regulation of Smurfs in cancers
|
Fu, Lin
|
|
|
104-105 |
P2 |
p. 102-116
|
article
|
| 127 |
The IL-1 family in tumorigenesis and antitumor immunity
|
Sun, Runzi
|
|
|
104-105 |
P2 |
p. 280-295
|
article
|
| 128 |
The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer
|
Noël, Grégory
|
|
2018
|
104-105 |
P2 |
p. 66-74
|
article
|
| 129 |
The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer
|
Missiaen, Rindert
|
|
2018
|
104-105 |
P2 |
p. 107-116
|
article
|
| 130 |
The Skp2 Pathway: A Critical Target for Cancer Therapy
|
Cai, Zhen
|
|
|
104-105 |
P2 |
p. 16-33
|
article
|
| 131 |
The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review
|
Butterfield, Lisa H.
|
|
2018
|
104-105 |
P2 |
p. 12-15
|
article
|
| 132 |
Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy
|
Agrawal, Lokesh
|
|
2018
|
104-105 |
P2 |
p. 26-38
|
article
|
| 133 |
Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy
|
Li, Tian
|
|
|
104-105 |
P2 |
p. 117-125
|
article
|
| 134 |
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
|
Dieci, Maria Vittoria
|
|
2018
|
104-105 |
P2 |
p. 16-25
|
article
|
| 135 |
Virtual screening of potential anticancer drugs based on microbial products
|
Pinto, Gaspar P.
|
|
|
104-105 |
P2 |
p. 1207-1217
|
article
|
| 136 |
‘Warburg effect’ controls tumor growth, bacterial, viral infections and immunity – Genetic deconstruction and therapeutic perspectives
|
Pouysségur, J.
|
|
|
104-105 |
P2 |
p. 334-346
|
article
|
Journal description